et the query remains on how you can predict these complications. It is actually relevant to consider prophylactic measures for avoiding hypercoagulability. Progressive diffuse abdominal pain with no significant alterations on coagulation profile or other danger components should raise the awareness for mesenteric thrombosis. Really, few instances of intestinal thrombosis exist inside the literature taking into consideration our patient certainly one of the very first cases of subacute mesenteric venous thrombosis in a non-severe COVID-19 patient. A lot more case reports and descriptive information are required in the literature to raise the index of suspicion for these kinds of complications.research concluding that there’s no distinction in collateral formation, recanalization and mortality, irrespective of whether anticoagulation had been prescribed or not. These findings emphasize the predominant role of inflammation, growing uncertainty of risk/benefit ratio of anticoagulation. When portal and superior mesenteric veins are impacted, anticoagulation appears a reasonable attitude, thinking of the risk of hepatic decompensation and bowel ischemia. Extra studies are necessary to consolidate this evidence and to EP Activator web establish well-defined recommendations in other situations (e.g., isolated thrombosis of splenic vein, as within this case).V T E D I AG N O S I S PB1175|Detection of Correct Ventricular Dysfunction in Acute Pulmonary Embolism by CT Scan: A Systematic Review and Metaanalysis N. Chornenki1; K. Poorzargar2; M. Shanjer2; L. Mbuagbaw2;PB1174|Does Anticoagulation Influence Outcome of Splenic Vein Thrombosis in Acute Pancreatitis L. Vieira; S. Lopes; R. Pombal; R. Neto; A. Magalh s; M. Figueiredo Immunohemotherapy Service, Vila Nova de Gaia/Espinho Hospital Centre, Vila Nova de Gaia, Portugal Background: Splanchnic venous thrombosis (SVT) is a wellestablished complication of acute pancreatitis (AP) and could affect splenic, portal and superior mesenteric veins, either isolated or in combination. Its pathogenesis is closely linked to inflammation, major to cellular infiltration, formation of pancreatic/peripancreatic collections that contribute to venous stasis and systemic activation of haemostasis. Aims: Description of a case of SVT AP-associated. Techniques: Collection of clinical data in SCl ico application. Final results: A 47-year-old female patient, with antecedents of prior AP secondary to hypertriglyceridemia, was CCR9 Antagonist list admitted to emergency division with pain in upper quadrants of abdomen, radiating towards the back, with nausea and vomiting, more than the past few hours. Through clinical, analytical and imaging evaluation, the diagnosis of AP secondary to hypertriglyceridemia was established. The patient was hospitalized and, four days later, as a consequence of clinical worsening, a computed tomography (CT) was performed, revealing splenic vein thrombosis and pancreatic necrosis. Enoxaparin in therapeutic dose was initiated. The patient remained hospitalized for 18 days and enoxaparin was replaced by rivaroxaban 20mg once daily at discharge. 3 months later, CT showed persistence of thrombosis, with perigastric/perisplenic collateral circulation. Contemplating this substantial collateral circulation, full recanalization was no longer anticipated. Anticoagulation was maintained for any total period of 6 months. Conclusions: Management of thrombosis in AP remains challenging. There is no consensus on anticoagulation within this setting, with someM. Crowther2; A. Delluc3; D. SiegalQueens University, Kingston, Canada; 2McMaster University,Hamilton, Cana
